|
References
(in alphabetical order) |
1.  
|
Aoki N, Harpel PC. Inhibitors
of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10: 24-41.
|
2.  
|
Arkin S, Cooper HA, Hutter JJ, Miller S,
Schmidt ML, Seibel NL, et al. Activated recombinant human coagulation
factor VII therapy for intracranial hemorrhage in patients with hemophilia
A or B with inhibitors. Results of the Recombinant Factor VIIa emergency-use
program. Hemostasis 1998; 28: 93-98. |
3.  
|
Astrup T. Tissue activators of plasminogen.
Fed Proc 1966; 25: 42-51. |
4.  
|
Bajaj MS, Rana SV, Wysolmerski RB, et al.
Inhibitor of the factor VIIa-tissue factor complex is reduced in patients
with disseminated intravascular coagulation but not in patients with
severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
|
5.  
|
Bernstein DE, Jeffers L, Erhardtsen E,
Reddy KR, Glazer S, Squiban P et al. Recombinant factor VIIa corrects
prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology
1997; 113: 1930-1937. |
6.  
|
Blombäck B, Blombäck M. The molecular
structure of fibrinogen. Ann NY Acad Sci 1972; 202: 77-97. |
7.  
|
Bregengaard C, Diness V, Hedner U. Effect
of recombinant factor VIIa on endotoxin-induced disseminated intravascular
coagulation in rabbits. Thromb Hemost 1993; 69: 749. |
8.  
|
Brinkhous KM, Hedner U, Garris JB, Diness
V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect
in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Proc Natl Acad Sci USA 1989; 86: 1382-1386. |
9.  
|
Budzinski AZ, Olexa SA, Pandya BV. Fibrin
ploymerization sites in fibrinogen and fibrin fragments. Ann NY Acad
Sci 1983; 408: 301-313. |
10.  
|
Castellino FJ. Biochemistry of human plasminogen.
Semin Thromb Hemost 1984;10: 18-23. |
11.  
|
Chesney CM, Piffer D, Colman RW. Subcellular
localization and secretion of factor V from human platelets. Proc
Natl Acad Sci 1981; 78: 5181-5184. |
12.  
|
Cines DB, Polack ES, Buck CA, et al. Endothelial
cells in physiology and in the pathophysiology of avascular disorders.
Blood 1998; 91: 3627-3261. |
13.  
|
Cohen I, Blankenberg TA, Borden D, et al.
Factor XIIIa catalysed cross-linking of platelet and muscle actin.
Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-375.
|
14.  
|
Conlan MG, Hoots WK. Disseminated intravascular
coagulation and hemorrhage in hemophilia B following elective surgery.
Am J Hematol 1990; 35: 203-207. |
15.  
|
Davey RJ, Shashaty GG, Rath CE. Acute coagulopathy
following infusion of prothrombin complex concentrate. Am J Med 1976;
60: 719-722. |
16.  
|
Davie EW, Ratnoff OD. Waterfall sequence
for intrinsic blood clotting. Science 1964; 145: 1310-1312. |
17.  
|
Dieval J, Nguyen G, Gross S, et al. A life-long
bleeding disorder associated with a deficiency of plasminogen activator
inhibitor type 1. Blood 1991; 77: 528-532. |
18.  
|
Egeberg O. Inherited antithrombin deficiency
causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530. |
19.  
|
Esmon CT. Regulation of blood coagulation.
Biochemica et Biophysica Acta 2000; 1477: 349-360. |
20.  
|
Folk JE, Finlayson JS. The Î (g-glutamyl)
lysine crosslink and the catalytic role of transglutaminases. Adv
Protein Chem 1977; 31: 1-133. |
21.  
|
Forbes CD, Thomas SP, et al (eds). Haemostasis
and Thrombosis, 1994; 3rd ed. Edinburgh, Churchill Livingstone 59-285.
|
22.  
|
Friederich PW, Levi M, Bauer K, Vlasuk
GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller
HR. Ability of Recombinant Factor VIIa to Generate Thrombin During
Inhibition of Tissue Factor in Human Subjects. Circulation 2001; 103:
2555-2559. |
23.  
|
Furie B, Furie BC. Molecular and cellular
biology of blood coagulation. N Engl J Med 1992; 326: 800-806. |
24.  
|
Girard P, Nony P, Erhardtsen E, Delair
S, Ffrench P, Dechavanne M et al. Population pharmacokinetics of recombinant
factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb
Hemost 1998; 80: 109-113. |
25.  
|
Green D. Complications associated with
the treatment of hemophiliacs with inhibitors. Hemophilia 1999; 5
(suppl 3): 11-17. |
26.  
|
Hay CR, Negrier C, Ludlam CA.
The treatment of bleeding in acquired hemophilia with recombinant
factor VIIa: a multicentre study. Thromb Hemost 1997; 78: 1463-1467.
|
27.  
|
Hoffman M, Monroe III DM. The action of
high dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
In: Treatment of Bleeding and Thrombotic Disorders. Semin Hematology
(suppl) 2001;in press. |
28.  
|
Ingerslev J, Freidman D, Gastineau D, Gilchrist
G, Johnsson H, Lucas G, et al. Major surgery in hemophilic patients
with inhibitors using recombinant factor VIIa. Hemostasis 1996; 26
(suppl 1): 118-123. |
29.  
|
Ingerslev J, Knudsen L, Hvid I, Tange MR,
Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in
factor VII deficient patients. Hemophilia 1997; 3: 215-218. |
30.  
|
Kaplan KL, Broekman MJ, Chernoff A, et
al. Platelet a-granule proteins: Studies on release and subcellular
localization. Blood 1979; 53: 604-618. |
31.  
|
Key NS, Aledort LM, Beardsley D, Cooper
HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate
bleeding episodes using recombinant factor VIIa (Recombinant Factor
VIIa) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912-918.
|
32.  
|
Key NS, Aledort LM, Beardsley D, Cooper
HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate
bleeding episodes using recombinant factor VIIa (Recombinant Factor
VIIa) in hemophiliacs with inhibitors. Thromb Hemost 1998; 80: 912-918.
|
33.  
|
Kim HC, McMillan CW, White GC, et al. Purified
factor IX using monoclonal immunoaffinity technique: Clinical trials
in haemophilia B and comparison to prothrombin complex concentrates.
Blood 1992; 79: 568-575. |
34.  
|
Kluft C, Dooijewaard G, Emeis JJ. Role
of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13:
50-68. |
35.  
|
Konigsberg W, Kirchhofer D, Riederer MA,
Nemerson Y. The TF:VIIa complex: clinical significance, structure-function
relationships and its role in signaling and metastasis. Thromb Haemost.
2001;86:757-71. |
36.  
|
Kowalski E. Fibrinogen derivatives and
their biological activities. Semin Hematol 1968; 5: 45-59. |
37.  
|
Kristensen J, Killander A, Hippe E, Helleberg
C, Ellegard J, Holm M, et al. Clinical experience with recombinant
factor VIIa in patients with thrombocytopenia. Haemostasis 1996; (suppl
1) 26: 159-164. |
38.  
|
Liebman HA, Chediak J, Fink KI, Galvez
AG, Shah PC, Sham RL. Activated recombinant human coagulation factor
VII (recombinant Factor VIIa) therapy for abdominal bleeding in patients
with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63:
109-113. |
39.  
|
Lindley CM, Sawyer WT, Macik BG, Lusher
J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics
of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
|
40.  
|
Loskutoff DJ, Sawdey M, Keeton M, et al.
Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993;
70: 135-137. |
41.  
|
Lund-Hansen T, Petersen LC. Comparison
of enzymatic properties of human plasma FVIIa and human recombinant
FVIIa. Thromb Hemost 1987; 58: 270. Note for Guidance on Quality of
Biotechnological Products: Viral Safety Evaluation of Biotechnology
Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95
1995. Note for Guidance on Virus Validation Studies: The Design, Contribution
and Interpretation of Studies Validating the Inactivation and Removal
of Viruses. CPMP/BWP/268/95 1995; 75/318/EEC. |
42.  
|
Lusher JM, Roberts HR, Davignon G, Joist
JH, Smith H, Shapiro A, et al. A randomized, double-blind comparison
of two dosage levels of recombinant factor VIIa in the treatment of
joint, muscle and mucocutaneous hemorrhages in persons with hemophilia
A and B, with and without inhibitors. recombinant Factor VIIa Study
Group. Hemophilia 1998; 4: 790-798. |
43.  
|
Lusher JM, Shapiro SS, Palascak JE, et
al. Efficacy of prothrombin-complex concentrates in haemophiliacs
with antibodies to factor VIII: A multicenter therapeutic trial. N
Engl J Med 1980; 303: 421-425. |
44.  
|
Lusher JM. Early treatment with recombinant
factor VIIa results in greater efficacy with less product. Eur J HematoL
Suppl 1998; 61: 7-10. |
45.  
|
MacFarlane RG. An enzyme cascade in the
blood clotting mechanism, and its function as a biological amplifier.
Nature 1964; 202: 498-499. |
46.  
|
McPherson J, Teague L, Lloyd J, Jupe D,
Rowell J, Ockelford P, et al. Experience with recombinant factor VIIa
in Australia and New Zealand. Hemostasis 1996; 26 Suppl 1: 109-117.
|
47.  
|
Meijer K, Peters FTM, van der Meer J. Recurrent
severe bleeding from gastrointestinal angiodysplasia in a patient
with von Willebrand's disease, controlled with recombinant factor
VIIa. Blood Coag Fibrin 2001;12: 211-213. |
48.  
|
Moisescu E, Ardelean I, Simion I, Muresen
A, Ciupan R. Recombinant factor VIIa treatment of bleeding associated
with acute renal failure. Blood Coagul Fibrinolysis 2000; 11: 575-577.
|
49.  
|
Monroe DM, Hoffman M, Allen G, Roberts
H. The factor VII-platelet interplay: Effectiveness of recombinant
factor VIIa in the treatment of bleeding in severe thrombocytopathia.
Sem Throm Hemost 2000; 26: 373-377. |
50.  
|
Nemerson Y, Esnouf MP. Activation of a
proteolytic system by a membrane lipoprotein: mechanism of action
of tissue factor. Proc Natl Acad Sci USA 1973; 70: 310-314. |
51.  
|
Nemerson Y. The tissue factor pathway of
blood coagulation. Semin Hematol 1992; 29: 170-176. |
52.  
|
Ohga S, Saito M, Matzukazi A, et al. Disseminated
intravascular coagulation in a patient with haemophilia B during factor
IX replacement therapy. Br J Haematol 1993; 84: 343-345. |
53.  
|
Peters M, Heijboer H. Treatment of a patient
with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant
factor VIIa [letter]. Thromb Haemost 1998; 80: 352. |
54.  
|
Poon MC, Demers C, Jobin F, Wu JW. Recombinant
factor VIIa is effective for bleeding and surgery in patients with
Glanzmann thrombasthenia. Blood 1999;94: 3951-3953. |
55.  
|
Rapaport SI. The extrinsic pathway inhibitor:
A regulator of tissue factor-dependent blood coagulation. Thromb Haemost
1991; 66: 6-15. |
56.  
|
Repke D, Gemmell CH, Guha A, Turitto VT,
Broze GJJ, Nemerson Y. Hemophilia as a defect of the tissue factor
pathway of blood coagulation: effect of factors VIII and IX on factor
X activation in a continuous-flow reactor. Proc Natl Acad Sci USA
1990; 87: 7623-7627. |
57.  
|
Revesz T, Arets B, Bierings M, van den
Bos C, Duval E. Recombinant factorVIIa in severe uremic bleeding.
Thromb Haemost 1998; 80: 353. |
58.  
|
Roberts H, Monroe DM, Hoffman M. Molecular
biology and biochemistry of the coagulation factors and pathways of
haemostasis. In: Beutler E et al,(eds). Williams Haematology. New
York: Mc-Graw-Hill Medical PublishingDivision, 2001: 1409-1434. |
59.  
|
Roberts HR. Clinical experience with activated
factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998;
(suppl 1) 9: S115-S118. |
60.  
|
Roberts HR. Clinical experience with activated
factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998;
9 (suppl 1): S115-S118. |
61.  
|
Rosenberg RD, Rosenberg JS. Natural anticoagulant
mechanisms. J Clin Invest 1984; 74: 1-6. |
62.  
|
Ruggeri ZM, Ware J. von Willebrand factor.
FASEB J 1993; 7: 308-316. |
63.  
|
Sakai T, Lund-Hansen T, Thim L, Kisiel
W. The gamma-carboxyglutamic acid domain of human factor VIIa is essential
for its interaction with cell surface tissue factor. J Biol Chem 1990;
265: 1890-1894. |
64.  
|
Sakata Y, Aoki N. Cross-linking of a2-plasmin
inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980;
65: 290-297. |
65.  
|
Santagostino E, Gringeri A, Mannucci PM.
Home treatment with recombinant activated factor VII in patients with
factor VIII inhibitors: the advantages of early intervation. Br J
Hematol 1999; 104: 22-26. |
66.  
|
Scharrer I. Recombinant factor VIIa for
patients with inhibitors to factor VIII or IX or factor VII deficiency.
Hemophilia 1999; 5: 253-259. |
67.  
|
Shapiro AD, Gilchrist GS, Hoots WK, Cooper
HA, Gastineau DA. Prospective, randomised trial of two doses of recombinant
Factor VIIa (Recombinant Factor VIIa) in haemophilia patients with
inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778. |
68.  
|
Shapiro AD, Gilchrist GS, Hoots WK, Cooper
HA, Gastineau DA. Prospective, randomised trial of two doses of recombinant
Factor VIIa (Recombinant Factor VIIa) in hemophilia patients with
inhibitors undergoing surgery. Thromb Hemost 1998; 80: 773-778. |
69.  
|
Sie P, Dupouy D, Pichon J, et al. Constitutional
heparin co-factor II deficiency associated with recurrent thrombosis.
Lancet 1985; 2: 414-416. |
70.  
|
Sixma JJ. Interaction of blood platelets
with the vessel wall. In Bloom AL, |
71.  
|
Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten
EP, et al. The effect of activated prothrombin-complex concentrate
(FEIBA) on joint and muscle bleeding in patients with haemophilia
A and antibodies to factor VIII: A double-blind clinical trial. N
Engl J Med 1981; 305: 717-721. |
72.  
|
Small M, Lowe GDO, Douglas JT, et al. Factor
IX thrombogenicity: In vivo effects on coagulation activation and
a case report of disseminated intravascular coagulation. Thromb Haemost
1982; 48: 76-77. |
73.  
|
Suzuki K, Nishioka J, Hashimoto S. Protein
C inhibitor. Purification from human plasma and characterization.
J Biol Chem 1983; 258: 163-168. |
74.  
|
Tengborn L, Petruson B. A patient with
Glanzmann thrombasthenia and epistaxis successfully treated with recombinant
factor VIIa [letter]. Thromb Haemost 1996; 75: 981-982. |
75.  
|
Thim L, Bjoern S, Christensen M, Nicolaisen
EM, Lund-Hansen T, Pedersen AH, et al. Amino acid sequence and posttranslational
modifications of human factor VIIa from plasma and transfected baby
hamster kidney cells. Biochemistry 1988; 27: 7785-7793. |
76.  
|
Tollefsen DM, Majerus DW, Blank MK. Heparin
cofactor II: Purification and properties of a heparin-dependent inhibitor
of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169. |
77.  
|
Varon D, Martinowitz U, Heim M (Guest editors).
State of the art. Inhibitors of coagulation factors. Hemophilia 1998;
4: 538-628. |
78.  
|
White JG, Gerrard JM. Ultrastructural features
of abnormal platelets. A review. Am J Pathol 1976; 83: 589-632. |
79.  
|
Wildgoose P, Nemerson Y, Hansen LL, Nielsen
FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa
in hemophilia A and B patients. Blood 1992; 80:25-28. |
80.  
|
Zucker MB, Broekman MJ, Kaplan KL. Factor
VIII-related antigen in human blood platelets. J Lab Clin Med 1979;
94: 675-682. |